Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry-Reference-Cited by-同舟云学术

Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry

Published:2017-04 Issue:4 Volume:213 Page:688-695
ISSN:0002-9610
Container-title:The American Journal of Surgery
language:en
Short-container-title:The American Journal of Surgery

Author:

Martin Robert C.G.,Bruenderman Elizabeth,Cohn Allen,Piperdi Bilal,Miksad Rebecca,Geschwind Jean-Francois,Goldenberg Alec,Sanyal Arun,Zigmont Ellen,Babajanyan Svetlana,Foreman Pamela,Mantry Parvez,McGuire Brendan,Gholam Pierre

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference26 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J cancer J Int cancer,2010

2. Hepatocellular carcinoma;El-Serag;N. Engl J Med,2011

3. Hepatocellular carcinoma;Forner;Lancet,2012

4. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis;Mazzaferro;N. Engl J Med,1996

5. The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation;Roh;Clin Transplant,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors;Hepatology Research;2024-07-26

2. Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT);Updates in Surgery;2024-05-07

3. Current status and prospect of treatments for recurrent hepatocellular carcinoma;World Journal of Hepatology;2023-02-27

4. Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments;Transplantation;2022-08-02

5. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation;Future Oncology;2022-06